RCMG Inc. is pleased to announce that the results of research using the "HBsAgGi ELISA" kit, which is available from our company, have been published in the Hepatology Research by Dr. Ritsuzo Kozuka and Dr. Masaru Enomoto of Osaka Metropolitan University.
Paper Title：
Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy
https://pubmed.ncbi.nlm.nih.gov/38323994/
RCMG Inc. is pleased to announce that the abstract on the correlation of HBsAgGi (HB surface antigen glycan isomer) with HBV-DNA and HBV-RNA virions in clinical samples has been accepted for the poster presentation at the Asian Pacific Association for the Study of the Liver (APASL) Annual Meeting 2024 (Kyoto, Mar. 27-31, 2024).
Website
https://www.apasl2024kyoto.org
RCMG Inc. is pleased to announce the publication of a review article, describing RCMG’s HBsAgGi ELISA kit, in Pathogens.
Dr. Ivana Lazarevic and colleagues at University of Belgrade published a review on hepatitis B surface antigen isoforms. In this review, the HBsAgGi ELISA is presented as a potential biomarker for monitoring HBV infection.
Paper Title：
Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies
RCMG Inc. is pleased to announce that the poster of the biochemical characteristics of HBsAgGi (HB surface antigen glycan isomer) and measuring HBsAgGi of clinical samples was presented at the AASLD The Liver Meeting® 2023 (Boston, Nov. 10-14, 2023).
Title: Hepatitis B virus surface antigen glycan isomer (HBsAgGi) as a new glyco-biomarker to detect infectious HBV virions
RCMG Inc. is pleased to announce that the abstract of the biochemical characteristics of HBsAgGi (HB surface antigen glycan isomer) and measuring HBsAgGi of clinical samples has been accepted for the poster presentation at the AASLD The Liver Meeting® 2023 (Boston, Nov. 10-14, 2023).
AASLD The Liver Meeting® 2023
We are pleased to announce that the results of research using the "HBsAgGi ELISA" kit, which is available from our company, have been published in the Journal of Viral Hepatitis by Dr. Taiki Okumura and Prof. Takeshi Umemura of Shinshu University.
Paper Title：
Serum Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients
https://pubmed.ncbi.nlm.nih.gov/37363934/
In this paper, 124 chronic hepatitis B patients, including 2 asymptomatic carriers, 10 inactive carriers, 97 chronic hepatitis, and 15 cirrhosis, were studied for the clinical significance of serum HBsAgGi levels, and the following findings were reported.
Based on the results, the paper discusses the potential usefulness of HBsAgGi as a novel biomarker for evaluating the pathogenesis of chronic hepatitis B, both for predicting HCC onset and for evaluating disease status of patients during nucleos(t)ide analogue therapy.
RCMG Inc. is pleased to announce two presentations by our customers regarding studies using HBsAgGi＊1 ELISA Kit at the 59th Annual Meeting of the Japan Society of Hepatology (Nara, June 15-16, 2023).
Website (Japanese only)
https://site2.convention.co.jp/jsh59/
＊1：HBsAgGi (HB surface antigen glycan isomer)
A recombinant monoclonal antibody against HBsAg glycan isomer (HBsAgGi) was generated by using O-glycosylated PreS2 peptide. Compared to traditional HBsAg-testing which recognizes all viral particles, HBsAgGi specifically recognizes infectious HBV particles (DNA virion).
https://med-glycosci.com/researchproducts.html#custom-html-8s
HBsAgGi antibody and HBsAgGi ELISA kit, which can measure infectious HBV particles described above are now available for research use only and can be purchased from RCMG Inc. and our distributor, FUJIFILM Wako Pure Chemical Corporation.
More detail information is available at our Projects and Research Products page.
RCMG, Inc. is pleased to announce the content of poster presentation of the HBsAgGi＊1 at the EASL Congress 2023 (Vienna, Austria, 21-24 June 2023).
Poster number : 257-FRI
Title: A new glyco-biomarker for measuring infectious hepatitis B virus targeting surface antigen glycan isomer (HBsAgGi)
Presenter: Kiyohiko Angata
https://www.easlcongress.eu/wp-content/uploads/2023/06/EASL_2023_Congress_Abstracts_version1_6June.pdf
EASL Congress 2023 webpage: https://www.easlcongress.eu/
＊1：HBsAgGi (HB surface antigen glycan isomer)
A recombinant monoclonal antibody against HBsAg glycan isomer (HBsAgGi) was generated by using O-glycosylated PreS2 peptide. Compared to traditional HBsAg-testing which recognizes all viral particles, HBsAgGi specifically recognizes infectious HBV particles (DNA virion).
https://med-glycosci.com/researchproducts.html#custom-html-8s
RCMG Inc. is pleased to announce that the abstract of the biochemical characteristics and pilot clinical results of HBsAgGi has been accepted for the poster presentation at the EASL Congress 2023 (Vienna, Austria, 21-24 June 2023).
EASL CONGLESS 2023
https://easl.eu/
RCMG Inc. is pleased to announce that it has filed to the Ministry of Health, Labour and Welfare for approval to manufacture and market "HBsAgGi＊1 Assay Kit" as an in vitro diagnostic product in Japan.
This product is intended to measure infectious HBV-DNA-containing particles and is planned to be used in assisting the diagnosis of HBV-infectious status of chronic hepatitis B patients and in monitoring their treatment and progress.
＊1：HBsAgGi (HB surface antigen glycan isomer)
A recombinant monoclonal antibody against HBsAg glycan isomer (HBsAgGi) was generated by using O-glycosylated PreS2 peptide. Compared to traditional HBsAg-testing which recognizes all viral particles, HBsAgGi specifically recognizes infectious HBV particles (DNA virion).
https://med-glycosci.com/researchproducts.html#custom-html-8s
References:
1. Murata A, Angata K, Sogabe M, et al. Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy. BMC Gastroenterol. 22: 270, 2022.
2. Angata K, Wagatsuma T, Togayachi A, et al. O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection. Biochim Biophys Acta Gen Subj. 186: 130020, 2022.
RCMG Inc. is pleased to announce that the first clinical study paper for HBsAgGi ELISA, entitled “Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy” has been published in BMC Gastroenterology (https://pubmed.ncbi.nlm.nih.gov/35641912/).
The new study aimed to evaluate serum HBsAgGi levels in 47 patients with chronic hepatitis B (CHB) treated with nucleos(t)ide analogs (NAs).
Comparison of HBsAgGi levels with other markers (HBV-DNA, HBsAg, and HBcrAg) at the baseline and after 48 weeks of NA therapy demonstrated that the HBsAgGi levels significantly correlated with HBV-DNA. Both HBV-DNA and HBsAgGi levels were decreased after 48 weeks of NA therapy, indicating HBsAgGi as a novel potential biomarker to monitor infectious HBV particles in patients receiving NA therapy. Immunoprecipitation assays demonstrated that the HBsAgGi antibody can enrich HBV particles containing HBV-RNA as well as HBV-DNA. Thus, the paper indicates the usefulness of the HBsAgGi in clinical study of HBV.
*Our research team previously found that the HBsAgGi (HB surface antigen glycan isomer) antibody is a monoclonal antibody specific to O-glycosylated PreS2 on M-HBs, which is predominantly expressed by HBV-DNA-containing viral particles.
“O-glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection”
Angata et al. (2021) Biochim Biophys Acta Gen Subj. 1866:130020
https://pubmed.ncbi.nlm.nih.gov/34582939/
HBsAgGi antibody and HBsAgGi ELISA kit, which can measure infectious HBV particles described above are now available for research use only and can be purchased from RCMG Inc. and our distributor, FUJIFILM Wako Pure Chemical Corporation.
More detail information is available at our Projects and Research Products page.
RCMG Inc. (Location: 2-1-6 Sengen, Plaza Suite 106, Tsukuba, Ibaraki 305-0047, Japan) has signed a sales contract for reagents, etc. in Japan and overseas with FUJIFILM Wako Pure Chemical Corporation (Head Office Location: 1-2 Doshomachi 3-Chome, Chuo-ku, Osaka 540-8605, Japan).
■FUJIFILM Wako Pure Chemical Corporation
Company Name: FUJIFILM Wako Pure Chemical Corporation
Representative Director: President Kazuo Shiraki
Head Office: 1-2 Doshomachi 3-Chome, Chuo-ku, Osaka 540-8605, Japan
Founded: 1922
Scope of Business: Providing laboratory chemicals, specialty chemicals and diagnostic reagents
Inquiries
RCMG Inc.
Email: marketing@medglyco.com
FUJIFILM Wako Pure Chemical Corporation
Email: ffwk-labchem-tec@fujifilm.com
Glyco-S ELISA system can measure HBsAg glycosylation of genotype A, B, C, and D.
The glycosylation of HBV is involved in HBV secretion and immune evasion. It is reasonable that the glycosylation on the envelop protein (HBsAg) affects responses of the HBV drugs related to HBV formation inhibition, immune responses, etc. RCMG’s new Glyco-S ELISA system can compare the glycosylation state of HBsAg in serum samples with the amount of S-HBsAg (qHBsAg). All HBsAg containing “a-determinant” can be applied to measure Glyco-S as shown in the figure. HBsAg of genotype A, B, C, and D expressed from CHO cells were tested by Glyco-S ELISA system.
New Contract Service: By using Glyco-S ELISA, RCMG will quantify the extent of glycosylation on HBsAg directly from your samples including clinical serum and non-clinical samples.
More detail information on this service is available at our PRODUCTS/SERVICES page.
RCMG, Inc. is pleased to announce that it has launched a new service for measuring genotype B in your samples as a Contract service [Quantifying HBsAgGi-gB].
A new antibody, HBsAgGi-gB (HB surface antigen glycan isomer of genotype B), recognizing PreS2 domain of genotype B HBsAg has been established, in addition to HBsAgGi-gC antibody specific to O-glycosylated Pre-S2 on M-HBs. HBV particles captured by HBsAgGi antibodies differ from those captured by S-HBsAg antibody. By using HBsAgG antibodies, we established new ELISA systems to measure HBV DNA- or HBV RNA-containing viral particles of genotype B and C.
By using HBsAgGi ELISA, RCMG will quantify the amount of infectious HBV containing M-HBsAg directly from your clinical or non-clinical samples.
More detail information on this service is available at our PRODUCTS/SERVICES page.
RCMG Inc. is pleased to announce that the new product [HBsAgGi ELISA Kit] to measure O-glycosylated HB surface antigen in HBV particle is launched.
In HBV patients, HBV particles consist of infectious HBV DNA particles and non-infectious particles without DNA or RNA. Non-infectious particles are mainly covered with S-HBsAg, while HBV DNA-containing particles are covered with S-, M- and L-HBsAg. HBsAgGi (HB surface antigen glycan isomer) antibody is a monoclonal antibody specific to O-glycosylated Pre-S2 on M-HBsAg. Thus, HBV particles captured by HBsAgGi differ from those captured by S-HBsAg antibody. Our proprietary HBsAgGi ELISA kit is suitable to measure HBV DNA-containing viral particles.
By using HBsAgGi ELISA Kit, you can quantify the amount of infectious HBV containing O-glycosylated M-HBsAg directly from samples including patients’ serum.
More detail information on this service is available at our PRODUCTS/SERVICES page.
RCMG Inc. is pleased to announce that the new contract service [HBsAgGi ELISA] to measure O-glycosylated HB surface antigen in HBV particle is launched.
HBsAgGi (HB surface antigen glycan isomer) is a monoclonal antibody specific to O-glycosylated Pre-S2 on M-HBs, which are predominantly present in infectious HBV particles. HBV particles captured by HBsAgGi differ from those captured by S-HBsAg antibody. By using HBsAgGi, we established for the first time a new ELISA system to measure HBV DNA-containing viral particle. Our research team also found that HBsAg ELISA can measure HBV RNA-containing viral particles after NUC treatment.
By using HBsAgGi ELISA, we will quantify the amount of infectious HBV containing O-glycosylated M-HBsAg directly from samples including patients’ serum.
New Contract Service: By using HBsAgGi ELISA, RCMG will quantify the amount of infectious HBV containing O-glycosylated M-HBsAg directly from your samples including patients’ serum.
More detail information on this service is available at our PRODUCTS/SERVICES page.
RCMG Inc. is pleased to announce that the new contract service [Glyco-S ELISA] to measure glycosylation level of HB surface antigen (HBsAg) is launched.
HBV is glycosylated by the host liver cells and secreted into blood. The glycosylation of HBV is involved in HBV formation and immune evasion. Our research team also found that the glycosylation on HBsAg affects immune responses. This time, RCMG successfully established the new proprietary ELISA system (Glyco-S ELISA) to measure and compare the glycosylation state of HBsAg in serum samples with the amount of S-HBsAg (qHBsAg).
New Contract Service: By using Glyco-S ELISA, RCMG will quantify the extent of glycosylation on S-HBsAg directly from your samples including clinical serum and non-clinical samples.
More detail information on this service is available at our Research Products/Contract Services page.
RCMG Inc. is pleased to announce that the fist paper for HBsAgGi, entitled “O-Glycosylated HBsAg peptide can induce specific antibody neutralizing HBV infection” were published in Biochimica et Biophysica Acta - General Subjects（https://pubmed.ncbi.nlm.nih.gov/34582939/） under research collaboration with National Institute of Advanced Industrial Science and Technology (AIST).
Our research team previously found that the specific glycan structure on HB surface antigen that predominantly expressed by DNA virion-containing viral particle. This time, we successfully established the new monoclonal antibody against the specific structure and demonstrated that the antibody strongly blocked HBV infection to human hepatocytes in vitro compared with clinical available HBIG (Human anti-HBs ImmunoGlobulin).
HBsAgGi (HB surface antigen glycan isomer) is a monoclonal antibody specific to O-glycosylated Pre-S2 on M-HBs, which is the specific glycan structure described above. HBsAgGi is now available for research use only and can be purchased from RCMG Inc. More detail information is available at our PROJECTS and PRODUCTS page.
Research results in which Drs. Narimatsu (former CEO) and Angata (CEO) of our company participated were published in the journal “Oncology Letters.”
Boottanun P, Ino Y, Shimada K, Hiraoka N, Angata K, Narimatsu H. Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma.
Oncol Lett. 2021 22(5):760. doi: 10.3892/ol.2021.13021.
Research results in which Dr. Narimatsu (CEO) and Sogabe (Researcher) of our company participated were published in the journal “Glycobiology.”
Noro E, Matsuda A, Kyoutou T, Sato T, Tomioka A, Nagai M, Sogabe M, Tsuruno C, Takahama Y, Kuno A, Tanaka Y, Kaji H, Narimatsu H. N-glycan structures of Wisteria floribunda agglutinin-positive Mac2 binding protein in the serum of patients with liver fibrosis.
Glycobiology. 2021 cwab060. doi: 10.1093/glycob/cwab060.
RCMG has appointed Dr. Kiyohiko Angata as Chief Executive Officer. Dr. Narimatsu, previous CEO of RCMG, has been appointed as Chairman of the Board.
Research results in which Dr. Angata (CEO) of our company participated were published in the journal “Journal of Proteome Research.”
Nagai-Okatani C, Zou X, Fujita N, Sogabe I, Arakawa K, Nagai M, Angata K, Zhang Y, Aoki-Kinoshita KF, Kuno A. LM-GlycomeAtlas Ver. 2.0: An Integrated Visualization for Lectin Microarray-based Mouse Tissue Glycome Mapping Data with Lectin Histochemistry.
J Proteome Res. 2021 20(4):2069-2075. doi: 10.1021/acs.jproteome.0c00907.
Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “PLOS ONE.”
Doi N, Ino Y, Angata K, Shimada K, Narimatsu H, Hiraoka N. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma.
PLoS One. 2020 15(11):e0242851. doi: 10.1371/journal.pone.0242851.
Research results in which Dr. Angata (Head of R&D) of our company participated were presented in the conference “HUPO Connect 2020.”
Nagai-Okatani C, Zou X, Fujita N, Sogabe I, Arakawa K, Nagai M, Angata K, Zhang Y, Aoki-Kinoshita KF, Kuno A. Update on LM-GlycomeAtlas: An integrated visualization for mouse tissue glycome mapping data with lectin histochemistry.
The 19th Human Proteome Organization World Congress via WEB on 0ctober 19-20, 2020.
Dr. Hisashi Narimatsu (CEO) of our company received ‘Dr. Kohzoh Imai Award’ at The 40th Annual Meeting of the Japan Society for Molecular Tumor Marker Research held at Hiroshima and WEB on September 30th, 2020.
Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Hepatology Research.”
This study demonstrated for the first time that glycogene would be a novel therapeutic target for HBV infection by regulating HBsAg and DNA secretion from hepatocytes.
Ito K, Angata K, Kuno A, Okumura A, Sakamoto K, Inoue R, Morita N, Watashi K, Wakita T, Tanaka Y, Sugiyama M, Mizokami M, Yoneda M, Narimatsu H. Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
Hepatol Res. 2020 50(10):1128-1140. doi: 10.1111/hepr.13552.
Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Frontiers in Oncology.”
This study comprehensively evaluated the glycogene profile in human HCC cell lines through novel RNA-seq/qPCR methodology and showed the advantage of glycoprotein-based biomarker compared to traditional protein-based biomarker.
Angata K, Sawaki H, Tsujikawa S, Ocho M, Togayachi A, Narimatsu H.
Glycogene Expression Profiling of Hepatic Cells by RNA-Seq Analysis for Glyco-Biomarker Identification.
Front Oncol. 2020 10:1224. doi: 10.3389/fonc.2020.01224.
Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Clinica Chimica Acta.”
Silsirivanit A, Matsuda A, Kuno A, Tsuruno C, Uenoyama Y, Seubwai W, Angata K, Teeravirote K, Wongkham C, Araki N, Takahama Y, Wongkham S, Narimatsu H. Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma.
Clin Chim Acta. 2020 510:142-149. doi: 10.1016/j.cca.2020.07.017.
Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Nature Methods.”
Yamada I, Shiota M, Shinmachi D, Ono T, Tsuchiya S, Hosoda M, Fujita A, Aoki NP, Watanabe Y, Fujita N, Angata K, Kaji H, Narimatsu H, Okuda S, Aoki-Kinoshita KF. The GlyCosmos Portal: a unified and comprehensive web resource for the glycosciences.
Nat Methods. 2020 17(7):649-650. doi: 10.1038/s41592-020-0879-8.
AIST and RCMG Inc. signed an exclusive licensing agreement under which RCMG Inc. will receive an exclusive license to develop and commercialize diagnostics for non-small cell lung cancer (NSCLC).
Research results in which Dr. Narimatsu (CEO) of our company participated were published in the journal, “Journal of Proteome Research.”
Matsuda A, Kuno A, Yoshida M, Wagatsuma T, Sato T, Miyagishi M, Zhao J, Suematsu M, Kabe Y, Narimatsu H. Comparative Glycomic Analysis of Exosome Subpopulations Derived from Pancreatic Cancer Cell Lines.
J Proteome Res. 2020 19(6):2516-2524. doi: 10.1021/acs.jproteome.0c00200.
AIST and RCMG Inc. signed an exclusive licensing agreement under which RCMG Inc. will receive an exclusive license to develop and commercialize diagnostics for small cell lung cancer (SCLC).
AIST and RCMG Inc. signed an exclusive licensing agreement under which RCMG Inc. will receive an exclusive license to develop and commercialize HBV diagnostics worldwide.
Research results in which Dr. Angata (Head of R&D) of our company participated were published in the journal “Molecules.”
Nagai-Okatani C, Aoki-Kinoshita KF, Kakuda S, Nagai M, Hagiwara K, Kiyohara K, Fujita N, Suzuki Y, Sato T, Angata K, Kuno A. LM-GlycomeAtlas Ver. 1.0: A Novel Visualization Tool for Lectin Microarray-Based Glycomic Profiles of Mouse Tissue Sections.
Molecules. 2019 24(16):2962. doi: 10.3390/molecules24162962.
Dr. Narimatsu (CEO) of our company presented as a speaker at the international conference held at University of Milano in Italy.
Narimatsu H. Development of liver fibrosis diagnostics, M2BPGi, using glycoscience technologies. The 25th International Symposium on Glycoconjugate, held at Milano on August 25-31, 2019.
RCMG Inc. was certified as the technology transfer company by National Institute of Advanced Industrial Science and Technology.
RCMG Inc. launched its website.RCMG Inc. launched its website.RCMG Inc. launched its website.RCMG Inc. launched its website.
Research results in which Drs. Narimatsu (CEO) and Angata (Head of R&D) of our company participated were published in the journal “Journal of Biological Chemistry.”
Nakane T, Angata K, Sato T, Kaji H, Narimatsu H. J Biol Chem. Identification of mammalian glycoproteins with type-I LacdiNAc structures synthesized by the glycosyltransferase B3GALNT2.
2019 294(18):7433-7444. doi: 10.1074/jbc.RA118.006892.
Research results in which Dr. Narimatsu (CEO) of our company participated were published in the journal, “Human Fertility.”
Hagiuda J, Takasaki N, Oya M, Ishikawa H, Narimatsu H. Mutation of GALNTL5 gene identified in patients diagnosed with asthenozoospermia.
Hum Fertil (Camb). 2020 23(4):226-233. doi: 10.1080/14647273.2018.1562239.
RCMG Inc. started business in Tsukuba to develop IVD and provide drug response services.RCMG Inc. started business
Service
Home
About Us
Products & Services
Research Products
Contract Services
Projects
News
Access
Contact
Japanese Website
Contact Us
